Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial

Light-chain (AL) amyloidosis remains incurable despite recent therapeutic advances. Given the activity of the lenalidomide-alkylating agent combination in myeloma, we designed this phase 2 trial of lenalidomide, cyclophosphamide, and dexamethasone in AL amyloidosis. Thirty-five patients, including 2...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Kumar, Shaji K., Hayman, Suzanne R., Buadi, Francis K., Roy, Vivek, Lacy, Martha Q., Gertz, Morie A., Allred, Jacob, Laumann, Kristina M., Bergsagel, Leif P., Dingli, David, Mikhael, Joseph R., Reeder, Craig B., Stewart, A. Keith, Zeldenrust, Steven R., Greipp, Philip R., Lust, John A., Fonseca, Rafael, Russell, Stephen J., Rajkumar, S. Vincent, Dispenzieri, Angela
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: American Society of Hematology 2012
Onderwerpen:
Clinical Trials and Observations
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3418771/
https://ncbi.nlm.nih.gov/pubmed/22504925
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-01-407791
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items